Research reveals measles vaccine efficacy
Virginia
Tech
For more cartoons by Mike Luckovich, CLICK HERE. |
"For
many infectious diseases, we rely on herd immunity to prevent outbreaks of
vaccine-preventable infections. Herd immunity is the protection of the 'herd,'
our population, by preventing infections in the vast majority people,"
said Kate Langwig, an infectious disease ecologist at Virginia Tech.
"We can calculate the percentage of the population that needs to be vaccinated to prevent diseases from spreading and maintain herd immunity. For some pathogens, like measles, the number that needs to vaccinated is very high because the measles virus spreads so easily."
"We can calculate the percentage of the population that needs to be vaccinated to prevent diseases from spreading and maintain herd immunity. For some pathogens, like measles, the number that needs to vaccinated is very high because the measles virus spreads so easily."
Langwig,
an assistant professor in the Department of Biological Sciences in the College
of Science at Virginia Tech, is researching ways in which vaccine efficacy can
be improved.
The
measles vaccine has been shown to have 97 percent efficacy, but
"understanding the circumstances that contribute to vaccine
ineffectiveness can help to better protect populations," Langwig said.
Langwig
and her lab ran mathematical modeling simulations to determine if vaccine
efficacy might be lower when individuals are exposed to high pathogen doses,
and when individuals vary in their susceptibility.
For
example, if you have been vaccinated against the measles, but someone sneezes
very close to your face, or you're caring for a sick kid who is sneezing,
coughing, etc., are you more likely to get sick?
In addition, if you're run down (maybe from chasing that kid the week earlier), are you more likely to get infected even if you've been vaccinated?
In addition, if you're run down (maybe from chasing that kid the week earlier), are you more likely to get infected even if you've been vaccinated?
Langwig
and her lab found in their simulations that vaccines are predicted to be less
effective at higher pathogen doses and when individuals in the population have
similar susceptibility.
These findings were recently published in Scientific Reports.
These findings were recently published in Scientific Reports.
"Susceptibility,
meaning how likely an individual is to get infected, is also important.
Individuals that are younger or have poor nutrition can be more likely to get
infected, even if they have been vaccinated. We found that populations that
have more variable susceptibility have higher vaccine efficacy," said
Langwig, an affiliated faculty member of the Global Change Center, an arm of
the Fralin Life Science Institute.
Langwig
and her lab were interested in validating their simulations with some
real-world data, so they did a systematic literature review with help from
Virginia Tech undergraduate researchers to determine whether there were
examples of diseases where vaccines efficacy is reduced at high doses.
"What
we found was a bit of a shock -- there are a very small number of studies that
test whether vaccines are effective across multiple pathogen doses. We reviewed
almost 6,000 articles and identified only about a dozen studies that had tested
vaccines across multiple pathogen doses. Within those few studies, the pattern
was generally consistent with our simulation -- vaccine efficacy tended to be
lower at high pathogen doses," said Langwig.
They
did find that some vaccines did offer complete protection regardless of
pathogen dose in several model organisms, suggesting that not all vaccines are
less effective when individuals are exposed to high doses.
Extrapolation
to human systems should be done with care, but this research helps increase the
understanding of host susceptibility, pathogen dose, and vaccine efficacy.
"One
thing that surprised us is that many scientists are vaguely aware that vaccines
might fail at high pathogen doses, but there were a very small number of
studies that had ever examined this," said Langwig.
Langwig
is currently collaborating with another lab to test vaccine efficacy and
different pathogen doses in a species of rainbow trout. They will continue to
design mathematical models to test predictions in real-world situations to
determine how populations can be further protected.